These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 22812381

  • 1. Aerosol-based efficient delivery of azithromycin to alveolar macrophages for treatment of respiratory infections.
    Togami K, Chono S, Morimoto K.
    Pharm Dev Technol; 2013; 18(6):1361-5. PubMed ID: 22812381
    [Abstract] [Full Text] [Related]

  • 2. Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections.
    Togami K, Chono S, Morimoto K.
    J Aerosol Med Pulm Drug Deliv; 2012 Apr; 25(2):110-5. PubMed ID: 22360316
    [Abstract] [Full Text] [Related]

  • 3. Aerosol-based efficient delivery of telithromycin, a ketolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections.
    Togami K, Chono S, Seki T, Morimoto K.
    Drug Dev Ind Pharm; 2010 Jul; 36(7):861-6. PubMed ID: 20515406
    [Abstract] [Full Text] [Related]

  • 4. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages.
    Togami K, Chono S, Morimoto K.
    Biopharm Drug Dispos; 2011 Oct; 32(7):389-97. PubMed ID: 21812004
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin.
    Lucchi M, Damle B, Fang A, de Caprariis PJ, Mussi A, Sanchez SP, Pasqualetti G, Del Tacca M.
    J Antimicrob Chemother; 2008 Apr; 61(4):884-91. PubMed ID: 18252692
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections.
    Chono S, Tanino T, Seki T, Morimoto K.
    Drug Metab Pharmacokinet; 2007 Apr; 22(2):88-95. PubMed ID: 17495415
    [Abstract] [Full Text] [Related]

  • 7. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections.
    Chono S, Tanino T, Seki T, Morimoto K.
    J Control Release; 2008 Apr 07; 127(1):50-8. PubMed ID: 18230410
    [Abstract] [Full Text] [Related]

  • 8. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis.
    Hwang SM, Kim DD, Chung SJ, Shim CK.
    J Control Release; 2008 Jul 14; 129(2):100-6. PubMed ID: 18538437
    [Abstract] [Full Text] [Related]

  • 9. [Pharmacokinetic and clinical studies with azithromycin (capsule) in the pediatric field. Pediatric Study Group of Azithromycin].
    Fujii R, Abe T, Tajima T, Terashima I, Meguro H, Sunakawa K, Yokota T, Akita H, Iwata S, Takeuchi Y.
    Jpn J Antibiot; 1995 Sep 14; 48(9):1074-92. PubMed ID: 7474330
    [Abstract] [Full Text] [Related]

  • 10. [Pharmacokinetic and clinical studies with azithromycin (fine granule) in the pediatric field. Pediatric Study Group of Azithromycin].
    Tajima T, Kobayashi M, Terashima I, Meguro H, Sunakawa K, Yokota T, Akita H, Iwata S, Takeuchi Y, Fujii R.
    Jpn J Antibiot; 1995 Sep 14; 48(9):1051-73. PubMed ID: 7474329
    [Abstract] [Full Text] [Related]

  • 11. [Designs of optimized microbial therapy systems of respiratory infections].
    Morimoto K.
    Yakugaku Zasshi; 2013 Sep 14; 133(1):81-92. PubMed ID: 23292024
    [Abstract] [Full Text] [Related]

  • 12. Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in vitro.
    Togami K, Chono S, Morimoto K.
    Biol Pharm Bull; 2013 Sep 14; 36(9):1494-9. PubMed ID: 23995662
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Amorphous azithromycin with improved aqueous solubility and intestinal membrane permeability.
    Aucamp M, Odendaal R, Liebenberg W, Hamman J.
    Drug Dev Ind Pharm; 2015 Sep 14; 41(7):1100-8. PubMed ID: 24980913
    [Abstract] [Full Text] [Related]

  • 15. [Intrapulmonary Pharmacokinetics and Drug Distribution Characteristics for the Treatment of Respiratory Diseases].
    Togami K.
    Yakugaku Zasshi; 2020 Sep 14; 140(3):345-354. PubMed ID: 32115551
    [Abstract] [Full Text] [Related]

  • 16. Relationship between azithromycin susceptibility and administration efficacy for nontypeable Haemophilus influenzae respiratory infection.
    Euba B, Moleres J, Viadas C, Barberán M, Caballero L, Grilló MJ, Bengoechea JA, de-Torres JP, Liñares J, Leiva J, Garmendia J.
    Antimicrob Agents Chemother; 2015 May 14; 59(5):2700-12. PubMed ID: 25712355
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and Histotoxic Profile of a Novel Azithromycin-Loaded Lipid-Based Nanoformulation.
    Rahman AU, Khan M, Khan MA, Rehman MU, Abdullah, Ahmed S.
    AAPS PharmSciTech; 2024 Jul 09; 25(6):157. PubMed ID: 38982006
    [Abstract] [Full Text] [Related]

  • 18. High azithromycin loading powders for inhalation and their in vivo evaluation in rats.
    Zhang Y, Wang X, Lin X, Liu X, Tian B, Tang X.
    Int J Pharm; 2010 Aug 16; 395(1-2):205-14. PubMed ID: 20595022
    [Abstract] [Full Text] [Related]

  • 19. [Clinical evaluation of azithromycin for respiratory infectious diseases].
    Oizumi K.
    Jpn J Antibiot; 2000 Jun 16; 53 Suppl B():72-81. PubMed ID: 12572090
    [Abstract] [Full Text] [Related]

  • 20. Inhaled azithromycin therapy.
    Hickey AJ, Lu D, Ashley ED, Stout J.
    J Aerosol Med; 2006 Jun 16; 19(1):54-60. PubMed ID: 16551215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.